Abiopharma

🔍 SPIEGELMAN DANIEL K (Executive)

Company: SPRUCE BIOSCIENCES, INC. (SPRB)

Report Date: 2025-12-11

Detailed Transactions and Holdings:

• Acquired 458 shares of Stock Option (Right to Buy) at $104.13 per share (Derivative)
  Date: 2025-12-11 | Code: A | Expires: 2030-09-08 | equity_swap_involved: 0 | shares_owned_after: 458.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2
• Sold 458 shares of Stock Option (Right to Buy) at $564.0 per share (Derivative)
  Date: 2025-12-11 | Code: D | Expires: 2030-09-08 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F3, F2
• Acquired 88 shares of Stock Option (right to buy) at $104.13 per share (Derivative)
  Date: 2025-12-11 | Code: A | Expires: 2031-05-19 | equity_swap_involved: 0 | shares_owned_after: 88.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2
• Sold 88 shares of Stock Option (right to buy) at $1143.0 per share (Derivative)
  Date: 2025-12-11 | Code: D | Expires: 2031-05-19 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F3, F2
• Acquired 400 shares of Stock Option (Right to Buy) at $104.13 per share (Derivative)
  Date: 2025-12-11 | Code: A | Expires: 2033-05-24 | equity_swap_involved: 0 | shares_owned_after: 400.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2
• Sold 400 shares of Stock Option (Right to Buy) at $169.5 per share (Derivative)
  Date: 2025-12-11 | Code: D | Expires: 2033-05-24 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F3, F2

Footnotes:

• F1: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five.
• F2: The shares subject to the option are fully vested and exercisable.
• F3: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date.
• F4: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options.